Refine your search
Co-Authors
- Saravana Kumar Jaganathan
- Aruna Priyadharshni Subramanian
- Agnes Aruna John
- Muthu Vignesh Vellayappan
- Arunpandian Balaji
- Bakiraj Gundumalai
- Ashok Kumar Jaganathan
- Aruna Priyadarshni Subramanian
- Rania Hussien Al-Ashwal
- A. Manikandan
- Joanne Zi En Soh
- Manikandan Ayyar
- Navaneetha Pandiyaraj Krishnasamy
- Rathanasamy Rajasekar
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Supriyanto, Eko
- Estimation and Comparison of Natural Frequency of Coronary Metallic Stents using Modal Analysis
Abstract Views :149 |
PDF Views:0
Authors
Saravana Kumar Jaganathan
1,
Aruna Priyadharshni Subramanian
1,
Agnes Aruna John
1,
Muthu Vignesh Vellayappan
1,
Arunpandian Balaji
1,
Eko Supriyanto
1,
Bakiraj Gundumalai
2,
Ashok Kumar Jaganathan
3
Affiliations
1 IJN-UTM Cardiovascular Engineering Centre, Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, Johor Bahru, 81310, MY
2 Research & Development Department, Bridgestone India Automotive, Mumbai, IN
3 Assistant Manager, Research and Development Wing, AVTEC Ltd, CK Birla Group, Hosur, IN
1 IJN-UTM Cardiovascular Engineering Centre, Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, Johor Bahru, 81310, MY
2 Research & Development Department, Bridgestone India Automotive, Mumbai, IN
3 Assistant Manager, Research and Development Wing, AVTEC Ltd, CK Birla Group, Hosur, IN
Source
Indian Journal of Science and Technology, Vol 8, No 12 (2015), Pagination:Abstract
A recent report states that more than 2,000,000 stents are used worldwide per year. Coronary artery obstruction is caused by the presence of high level of cholesterol which leads to ischemia. To prevent the elastic contraction of the artery that occurs immediately after the removal of the obstruction, typically a cardiovascular stent is placed. Structural integrity of the stent is an essential parameter determining the life span of the stent. In order to prevent the stent failure, we modelled a cardio vascular stent and subjected it to modal analysis to estimate the natural frequency of the stent. For this study three commonly used stent materials namely stainless steel (316L), cobalt-chromium alloy (CoCrMo) and titanium alloy (Ti6Al4V) were chosen. The natural frequencies were significantly different (P<0.05) for the three metallic stents at each corresponding modes. The vibrating modes at each frequency showed pronounced changes in their shapes for every stent material. The outcome of this work will be used by the medical product designers for designing new stents with better structural integrity by analyzing the modelled stent using ANSYS software before stent insertion, substituting in vivo experiment that is difficult and unpractical.
Keywords
Cardiovascular Stent, Coronary Artery Obstruction, Modal Shapes, Natural Frequency, Structural integrityFull Text
- Natural Frequency of Cancer Cells as a Starting Point in Cancer Treatment
Abstract Views :1222 |
PDF Views:148
Authors
Saravana Kumar Jaganathan
1,
Aruna Priyadarshni Subramanian
1,
Muthu Vignesh Vellayappan
1,
Arunpandian Balaji
1,
Agnes Aruna John
1,
Ashok Kumar Jaganathan
2,
Eko Supriyanto
1
Affiliations
1 IJN-UTM Cardiovascular Engineering Centre, Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Research and Development Wing, AVTEC Ltd, CK Birla Group, Hosur 635 114, IN
1 IJN-UTM Cardiovascular Engineering Centre, Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Research and Development Wing, AVTEC Ltd, CK Birla Group, Hosur 635 114, IN
Source
Current Science, Vol 110, No 9 (2016), Pagination: 1828-1832Abstract
Breast cancer and prostate cancer are the most common gender-specific types of cancer among women and men respectively, around the world. The most preferred treatment embraced by the patients is chemotherapy. The anticancer drugs developed and used so far cannot completely cure cancer at all stages and also exhibit some side effects in the patients who undergo chemotherapy. Besides this, some cancer cells eventually acquire resistance to many drugs and evade the treatment procedures. All these factors play a vital role in persuading the researches to find alternative modes of treatment for cancer. This communication proposes an unconventional mode of cancer treatment by determining the natural frequencies of normal and cancer cells. By utilizing these frequencies, it is possible to kill the cancer cells specifically, sparing the healthy cells. The normal and cancer cells in case of breast (MCF-10A, MCF-7) as well as prostate cancer (BPH, LNCap) are modelled as a sphere in ANSYS. The modal analysis is done in order to obtain their natural frequencies along with their mode shapes at different frequencies. The results show that the natural frequency of the normal cells is much higher than that of the cancer cells at each corresponding mode. The natural frequency is proportional to the mechanical properties of the cells and is insignificant with respect to the change in diameter of the cells. Thus, utilizing the natural frequency, cancer cells may be specifically targeted while the burdens of chemotherapy and drug resistance.Keywords
Breast Cancer, Modal Analysis, Natural Frequency, Prostate Cancer.Full Text
References
- American Cancer Society, Cancer facts and figures 2015; http://www.cancer.org/research/cancerfactsstatistics/cancerfactsFig.s2015/ (retrieved on 3 January 2015).
- Jaganathan, S. K., Can flavonoids from honey alter multidrug resistance. Med. Hypotheses, 2011, 76, 535–537.
- Davis, I. D., Birrell, S. N., Tilley, W. D. and Risbridger, G. P., Breast and prostate cancer: more similar than different. Nature Rev. Cancer, 2010, 10, 205–212.
- Shukla, S. K. and Lodwal, A., Experimental analysis of vibration on radial drilling machine using piezoelectric sensor. Bookman Int. J. Mech. Civ. Eng., 2013, 2, 2319–4286.
- Bao, G. and Suresh, S., Cell and molecular mechanics of biological material. Nature Mater., 2003, 2, 715–725.
- Ackerman, E., Resonances of biological cells. Bull. Math. Biophys., 1951, 13, 93–106.
- Lamb, H., On the vibrations of an elastic sphere. London Math. Soc. Ser., 1882, 13, 189–212.
- Chree, C., The equations of an isotropic elastic solid in polar and cylindrical coordinates their solution and application. Cambridge Philos. Soc., 1889, 14, 250–269.
- Jiang, H., Young, P. G. and Dichinson, S. M., Natural frequencies of vibration of layered hollow spheres using exact three dimensional elasticity equations. J. Sound Vibr., 1996, 195, 155–162.
- Zarandi, M. M., Bonakdar, A. and Stiharu, I., Investigations on natural frequencies of individual spherical and ellipsoidal bakery yeast cells. In COMSOL conference, 2010, pp. 5–6.
- Ketene, A. N., The AFM study of ovarian cell structural mechanics in the progression of cancer. M Sc thesis, Virginia Polytechnic Institute and State University, 2011, pp. 1–124.
- Ariffin, I., Supriyanto, E. and Salim, M., A novel tissue imaging method using short pulse magneto acoustic wave, 2011.
- Strohm, E. M. and Kolios, M. C., Measuring the mechanical properties of cells using acoustic microscopy. In 31st Annual International Conference of the IEEE EMBS Minneapolis, 2009, 2–6, 6041–6045.
- Bancroft, C., Electromagnetic heating effects in human tissue an exploration into microwave antenna designs for prostate TUMT; http://tesla.unh.edu/courses/ece994/StudentProjects/ChrisBancroft.pdf
- Barnkob, R., Augustsson, P., Magnusson, C., Lilja, H., Laurell, T. and Bruus, H., Measuring density and compressibility of white blood cells and prostate cancer cells by micro channel acoustophoresis. In 15th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Washington, 2011, pp. 127–129.
- Jaganathan, S. K. et al., Estimation and comparison of natural frequency of coronary metallic stents using modal analysis. Indian J. Sci. Technol., 2015, 8(12), 1–7.
- Rao, M. B., Collapsing cancer cells: exploiting the elasticity and natural frequency of a cancer cell’s cytoskeleton. In California State Science Fair, 2 April 2011.
- Wee, H. and Voloshin, A., Modal analysis of a spreading osteoblast cell in culturing. In Bioengineering Conference (NEBEC), Boston Marriott Newton, USA, 7–9 October 2012.
- Zarandi, M. M., Determination of mechanical properties of individual living cells. In Lib. Arch. Can., Temple University, Philadelphia, PA, USA, 16–18 March 2007, pp. 1–136.
- Geltmeier, A. et al., Characterization of dynamic behaviour of MCF7 and MCF10A cells in ultrasonic field using modal and harmonic analyses. PLoS ONE, 2015, 10(8), e0134999.
- Evidence for the Contemporary Clinical Pathway Quality Measures: Literature Review
Abstract Views :138 |
PDF Views:0
Authors
Affiliations
1 Clinical Science Department, Faculty of Biosciences and Engineering, University Technology Malaysia, Skudai, MY
2 IJN-UTM Cardiovascular Engineering, Clinical Science Department, Faculty of Biosciences and Medical Engineering University Technology Malaysia, Skudai, MY
1 Clinical Science Department, Faculty of Biosciences and Engineering, University Technology Malaysia, Skudai, MY
2 IJN-UTM Cardiovascular Engineering, Clinical Science Department, Faculty of Biosciences and Medical Engineering University Technology Malaysia, Skudai, MY
Source
Indian Journal of Science and Technology, Vol 9, No 34 (2016), Pagination:Abstract
Objectives: Clinical pathway effect on improving the healthcare quality still underestimated. An overview on clinical pathway current practice overview will be presented in the context of this paper. Methods/Statistical Analysis: A search for the medical literature was conducted to screen the contemporary evidence. We focused on finding the gold standard for clinical pathway quality measures and the current status of clinical pathway in Malaysia. Various databases (MEDLINE, EMBASE, Pub Med, COHRANCE library and CINAHEL) have been screened for 2000 to 2015 studies. Checklist of the preferred reporting items for systematic reviews and meta-analyses has been used as a guide for reporting. Findings: The search has identified 720 documents, of which 315 (44%) met the inclusion criteria of this study. Twenty meta-analysis studies have been found, while only nine have completely fulfilled the search inclusion criteria. Mostly they discussed the length of stay, patient outcome and cost from RCT (Randomized Clinical Trial) or EXP (experimental design) evidence as a quality indicator for the clinical pathway which may under represent the complexity nature of clinical pathway and ignored many aspects of care. The majority of publications in Malaysia found from (UKM) with similar heterogeneous focus on the outcome measures to what have been found in the overall literature. Interestingly, we found that no meta-analysis study has been conducted in Malaysia for clinical pathway. Application/Improvements: Current research on clinical pathway still limited. More Studies on the effect of clinical pathway on quality of care still needed with emphasize on the cofounding factors.Keywords
Clinical Pathway, Literature Review, Quality and Evidence based Medicine.Full Text
- Exploratory Study for Myocardial Infarction Clinical Pathway Compliance and Performance
Abstract Views :153 |
PDF Views:0
Authors
Affiliations
1 Clinical Science Department, Faculty of Biosciences and Engineering, University Technology Malaysia, Skudai, MY
2 IJN-UTM Cardiovascular Engineering, Clinical Science Department, Faculty of Biosciences and Medical Engineering University Technology Malaysia, Skudai, MY
1 Clinical Science Department, Faculty of Biosciences and Engineering, University Technology Malaysia, Skudai, MY
2 IJN-UTM Cardiovascular Engineering, Clinical Science Department, Faculty of Biosciences and Medical Engineering University Technology Malaysia, Skudai, MY
Source
Indian Journal of Science and Technology, Vol 9, No 34 (2016), Pagination:Abstract
Objectives: Although Clinical Pathway (CP) standardizes the patient care, poor compliance remains. The consistency of the expert’s opinion on the CPs significance to the pattern of Clinical Pathway completeness was explored. Methods/Statistical Analysis: Mixed method and data triangulation were used in this study. Two types of data were collected from one hospital for STEMI (St Elevation Myocardial Infarction) patients. Primary (Survey) and secondary (CP filled documents) data were collected. Clinical Pathway content analyses with descriptive statistics were conducted using SPSS version 22. The influence of design on the completeness of the document was investigated. Findings: The content analysis revealed four main care processes in STEMI Clinical Pathway (Medical assessment and nursing, Medication therapy and treatment, Education nutrition and rehabilitation and outcome variance). We found differences in the design of the documents. Most of the experts (58%) agreed on the importance of time to treatment, while 35% of the respondents have a strong agreement on the importance of fast action to treatment and nothing should delay the intervention. CP1 was holding the highest ratio of documents completeness despite the fact that CP2 and CP3 are the improved version of CP1. Application/Improvements: The variance of the expert opinion from the real Clinical Pathway performance indicated inconsistency between the knowledge and practice. Further explanation for the phenomenon is recommended.Keywords
Clinical Pathway, Completeness, Experts, Myocardial InfarctionFull Text
- Surface Modification of Titanium and its Alloys for the Enhancement of Osseointegration in Orthopaedics
Abstract Views :246 |
PDF Views:92
Authors
Affiliations
1 Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City 70000, VN
3 IJN-UTM Cardiovascular Engineering Centre, Universiti Teknologi Malaysia, Johor Bahru 81310, MY
4 Department of Chemistry, Bharath Institute of Higher Education and Research, Bharath University, Chennai 600 073, IN
1 Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City 70000, VN
3 IJN-UTM Cardiovascular Engineering Centre, Universiti Teknologi Malaysia, Johor Bahru 81310, MY
4 Department of Chemistry, Bharath Institute of Higher Education and Research, Bharath University, Chennai 600 073, IN
Source
Current Science, Vol 111, No 6 (2016), Pagination: 1003-1015Abstract
Titanium (Ti) and Ti-based alloys are the best promising orthopaedic metal transplants. The Young's modulus of Ti and bone are nearer and so Ti implants are known as osseointegrated implants. However, the need for enhancing the osseointegration, corrosion resistance and biocompatibility cannot be ruled out in promoting the Ti as a golden standard. This review describes various surface modifications like acid etching, sand blasting, surface coating, alkali-heat treatment, plasma treatment and ion implantation of Ti-based implants which are the best solutions to promote biocompatibility, osseointegration and ultimately the longevity of implants. In addition, it gives an outline to accomplish the risky task in orthopaedics like recovering skeletal function by replacing the damaged bone for human being survival and it will assist the energetic collaboration of specialists in materials science, chemistry and biology for the quality enhancement.Keywords
Corrosion Resistance, Osseointegration, Orthopaedics, Titanium and its Alloys, Surface Modification.Full Text
- An Insight into the Putative Role of Victuals Like Honey and its Polyphenols in Breast Cancer
Abstract Views :312 |
PDF Views:85
Authors
Aruna Priyadharshni Subramanian
1,
Agnes Aruna John
1,
Muthu Vignesh Vellayappan
1,
Arunpandian Balaji
1,
Saravana Kumar Jaganathan
2,
A. Manikandan
3,
Eko Supriyanto
4
Affiliations
1 Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, VN
3 Department of Chemistry, Bharath University, Chennai 600 073, IN
4 IJNU-TM Cardiovascular Engineering Center, Universiti Teknologi Malaysia, Skudai 81300, Johor, MY
1 Universiti Teknologi Malaysia, Johor Bahru 81310, MY
2 Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, VN
3 Department of Chemistry, Bharath University, Chennai 600 073, IN
4 IJNU-TM Cardiovascular Engineering Center, Universiti Teknologi Malaysia, Skudai 81300, Johor, MY
Source
Current Science, Vol 112, No 09 (2017), Pagination: 1839-1854Abstract
Diet plays a crucial role in cancer advancement as well as prevention. Breast cancer is the second leading cause of cancer death among women. Recent research links breast cancer with diet and some evidence for the preventive effect of diet against breast cancer was also documented. The growth of cancer cells is influenced by natural sweetener honey and its multitude of phenolic phytochemical components. Honey has been used medicinally by ancient Greeks and Egyptians and also traditionally exploited in Ayurveda and Chinese medicine. In this paper, the anti-cancer properties of honey and its phytochemical's action against breast cancer have been summarized. They result in apoptosis by enhancing reactive oxygen species level, activating mitochondrial pathway, initiation of pro-apoptotic and anti-apoptotic proteins, induction of p53 pathway that finally cause DNA fragmentation. However, there is a necessity for more proteomic and genetic-based experiments to understand its molecular mechanism to promote honey and its phenolic markers as plausible candidates for breast cancer treatment. Further, there is a need for quality check of honey available in the market, which warrants significant investigation by researchers in the food industry to ensure their attributes.Keywords
Anti-Cancer, Apoptosis, Breast Cancer, Honey, Phenolic.Full Text
References
- Defining Cancer. National Cancer Institute; available at: https://www.cancer.gov/
- Bernard, S. and Christopher, P., World Cancer Report, IARC Nonserial Publication. WHO Press, 2014.
- Breast Cancer Facts and Figures. American Cancer Society, 2014; http://www.cancer.org/research/cancerfactsstatistics/breastcancerf actsfigures2014/
- Gaffield, M. E., Culwell, K. R. and Ravi, A., Oral contraceptives and family history of breast cancer. Contraception, 2009, 80(4), 372–380.
- DNA to Diversity: Molecular Genetics and the Evolution of Animal Design, Blackwell, Oxford, 2001, 2nd edn.
- Lof, M. and Weiderpass, E., Impact of diet on breast cancer risk. Curr. Opin. Obstet. Gynecol., 2009, 21(1), 80–85.
- Tonelli, D., Gattavecchia, E., Ghini, S., Porrini, C., Celli, G. and Mercuri, A. M., Honey bees and their products as indicators of environmental radioactive pollution. J. Radioanal. Nucl. Chem., 1990, 141(2), 427–436.
- Spence, J., The Cartoon History of the Universe II from the springtime of China to the Fall of Rome-Gonick, Broadway Books, New York, 1994, pp. 15–16.
- Altman, N., The Honey Prescription: The Amazing Power of Honey as Medicine, Inner Traditions/Bear & Co., 2010, pp. 60–62.
- Jaganathan, S. K. and Mandal, M., Antiproliferative effects of honey and of its polyphenols: a review. BioMed. Res. Int., 2009, 830616, 1–13; http://dx.doi.org/10.1155/2009/830616.
- Saunders, C. and Jassal, S., Breast Cancer, Oxford University Press, Oxford, 2009, 1st edn, p. 13; https://global.oup.com/academic/product/breast-cancer-9780199558698?cc=my&lang=en&
- ‘Genome Dictionary’; Retrieved 6 June 2015.
- Duncan, J. A., Reeves, J. R. and Cooke, T. G., BRCA1 and BRCA2 proteins: roles in health and disease. Mol. Pathol., 1998, 51(5), 237–247.
- Dennis, J., Ghadirian, P. and Little, J., Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast, 2010, 19(6), 479–483.
- Sotiriou, C. and Pusztai, L., Gene-expression signatures in breast cancer. N. Engl. J. Med., 2009, 360(8), 790–800.
- Lind, M. J., Principles of cytotoxic chemotherapy. Medicine, 2008, 36(1), 19–23.
- Corrie, P. G. and Pippa, G., Cytotoxic chemotherapy: clinical aspects. Medicine, 2008, 36(1), 24–28.
- David, W. B., The chemical composition of honey. J. Chem. Educ., 2007, 84(10), 1643–1647.
- Yao, L., Jiang, Y. M., D’Arcy, B., Singanosung, R., Datta, N., Caffin, N. and Raymont, K., Quantitative high performance liquid chromatography analyses of flavonoids in Australian Eucalyptus honeys. J. Agric. Food Chem., 2004, 52(2), 210–214.
- Dimitrova, B., Gevrenova, R. and Anklam, E., Analysis of phenolic acids in honeys of different floral origin by solid-phase extraction and high-performance liquid chromatography. Phytochem. Anal., 2007, 18, 24–32.
- Jaganathan, S. K. and Mandal, M., Involvement of non-protein thiols, mitochondrial dysfunction, reactive oxygen species and p53 in honey-induced apoptosis. Invest. New Drugs, 2010, 28, 624–633.
- Ahmed, S. and Othman, N. H., Review of the medicinal effects of Tualang honey and a comparison with manuka honey. Malays. J. Med. Sci., 2013, 20(3), 6–13.
- Socha, R., Juszczak, L., Pietrzyk, S. and Fortuna, T., Antioxidant activity and phenolic composition of herbhoneys. Food. Chem., 2009, 113(2009), 568–574.
- Yao, L., Datta, N., Tomás- Barberán, F. A., Ferreres, F., Martos, I. and Singanosung, R., Flavonoids, phenolic acids and abscicic acid in Australian and New Zealand Leptospermum honeys. Food. Chem., 2003, 81, 159–168.
- Ioannis, K., Karabagias, Elpida, Dimitriou, Stavros and Kontakos, Michael, G. Kontominas, Phenolic profile, colour intensity, and radical scavenging activity of Greek unifloral honeys. Eur. Food. Res. Technol., 2016, 242(8), 1–10.
- Lachman, J., Orsák, M., Hejtmánková, A. and Kovářová, E., Honey and health 155 Evaluation of antioxidant activity and total phenolics of selected Czech honeys. LWT-Food. Sci. Technol., 2010, 43(1), 52–58.
- Aljadi, A. M. and Kamaruddin, M. Y., Evaluation of the phenolic contents and antioxidant capacities of two Malaysian floral honeys. Food Chem., 2004, 85, 513–518.
- Ferreira, I. C. F. R., Aires, E., Barreira, J. C. M. and Estevinho, L. M., Antioxidant activity of Portuguese honey samples: different contributions of the entire honey and phenolic extract. Food Chem., 2009, 114, 1438–1443.
- Fatimah Buba, Abubakar, Gidado and Aliyu, Shugaba, Analysis of biochemical composition of honey samples from North-East Nigeria. Biochem. Anal. Biochem., 2013, 2(3), 1000139– 1000146.
- Cossentini, M., Ferreres, F. and Tomás-Barberán, F. A., Flavonoid composition of tunisian honeys and propolis. J. Agric. Food Chem., 1997, 45, 2824–2829.
- Jaganathan, S. K., Can flavonoids from honey alter multidrug resistance? Med. Hypo., 2011, 76, 535–537.
- Jaganathan, S. K. and Mandal, M., Honey constituents and their apoptotic effect in colon cancer cells. J. ApiProd. ApiMed. Sci., 2009, 1(2), 29–36.
- Abdulaziz, S., Alqarni., Ayman, A. Owayss, Awad, A. Mahmoud, Physicochemical characteristics, total phenols and pigments of national and international honeys in Saudi Arabia. Arab. J. Chem., 2016, 9(1), 114–120.
- Schramm, D. D., Karim, M., Schrader, H. R., Holt, R. R., Cardetti, M. and Keen, C. L., Honey with high levels of antioxidants can provide protection to healthy human subjects. J. Agric. Food Chem., 2003, 51, 1732–1735.
- Manach, C., Scalbert, A., Morand, C. H., Rémesy, C. H. and Jimenez, L., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr., 2004, 79, 727–747.
- Manach, C., Williamsom, G., Morand, C. H., Scalbert, A. and Rémesy, C. H., Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 2005, 81, 230S–242S.
- Scalbert, A. and Williamson, G., Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130, 2073–2085.
- Alvarez-Suarez, J. M., Giampieri, F. and Battino, M., Honey as a source of dietary antioxidants structures, bioavailability and evidence of protective effects against human chronic diseases. Curr. Med. Chem., 2013, 20(5), 621–638.
- Tallarida, R. J., Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther., 2001, 298, 865–872.
- Choi, E. J. and Kim, G. H., 5-Fluorouracil combined with apigenin enhances anti-cancer activity through induction of apoptosis in humanbreast cancer MDA-MB-453 cells. Oncol. Rep., 2009, 22(6), 1533–1537.
- Ayşe, A. K., Ayşe, B., Miris, D., Didem, T. C., İrfan, D. and Hasan, V. G., Evaluation of effects of Quercetin (3, 3, 4, 5, 7pentohidroxyflavon) on apoptosis and telomerase enzyme activity in MCF-7 and NIH-3T3 cell lines compared with Tamoxifen. Balkan. Med. J., 2011, 28, 293–299.
- Huang, C., Lee, S. Y., Lin, C. L., Tu, T. H., Chen, L. H., Chen, Y. J. and Huang, H. C., Co-treatment with quercetin and 1,2,3,4,6-penta-O-galloyl- -D-glucose causes cell cycle arrest and apoptosis inhuman breast cancer MDA-MB-231 and AU565 cells. J. Agric. Food. Chem., 2013, 61(26), 6430–6445.
- Takahiro, E., Naoto, T., Hiroshi, N., Tadao, K., Kiyotaka, N. and Teruo, M., Synergistic inhibition of cancer cell proliferation with a combination of d-tocotrienol and ferulic acid. Biochem. Biophys. Res. Commun., 2014, 453(3), 606–611.
- Henry, P. C., Phillip, J. D. and Grace, C. Y., Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J., 1999, 340, 715–722.
- Kanokkarn, P., Supachai, Y., Songyot, A. and Pornngarm, L., Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol. Sin., 2009, 30(8), 1169–1176.
- Margaret, L. A., Simone, V. D. W. and Rod, J., Synergistic Antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. In vivo, 2005, 19, 69–76.
- Anna, V. T., Mari, J., Ioanna, C., Konstadia, G., Tiina, T., Vesa, V. and Paraskevi, M., Bioactivity of Greek honey extracts on breast cancer (MCF-7), prostate cancer (PC-3) and endometrial cancer (Ishikawa) cells: profile analysis of extracts. Food Chem., 2009, 116, 702–708.
- Mervat, M. A. and El-Gendy, In vitro, evaluation of medicinal activity of Egyptian honey from different floral sources as anticancer and antimycotic infective agents. J. Micro. Biochem. Technol., 2010, 2(5), 118–125.
- Jaganathan, S. K., Mandal, M. S., Saikat, K. J., Soumen, D. and Mandal, M., Studies on the phenolic profiling, anti-oxidant and cytotoxic activity of Indian honey: in vitro evaluation. Nat. Prod. Res., 2010, 24(14), 1295–1306.
- Jaganathan, S. K., Mondhe, D., Wani, Z. A., Pal, H. C. and Mandal, M., Effect of Honey and Eugenol on Ehrlich ascites and solid carcinoma. J. Biomed. Biotechnol., 2010, 1–5.
- Fauzi, A. N., Norazmi, M. N. and Yaacob, N. S., Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food Chem. Toxicol., 2011, 49(4), 871–878.
- Yaacob, N. S., Nengsih, A. and Norazmi, M. N., Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines. Evid. Based. Complement. Alternat. Med., 2013, 989841, 1–9; http://dx.doi.org/10.1155/2013/989841.
- Yaacob, N. S. and Ismail, N. F., Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7and MCF-10A cells. BMC Complement. Altern. Med., 2014, 14, 106–115.
- Saxena, S., Kumar, D., Maurya, G. S. and Sharma, A., Effect of radiation hygienization of honey on its health protective properties. Food. Biosci., 2014, 8, 14–20.
- Kadir, E. A., Sulaiman, S. A., Yahya, N. K. and Othman, N. H., Inhibitory effects of Tualang honey on experimental breast cancer in rats: a preliminary study. Asian. Pac. J. Cancer. Prev., 2013, 14(4), 2249–2254.
- Orsolić, N., Knezević, A., Sver, L., Terzić, S., Hackenberger, B. K. and Basić, I., Influence of honey bee products on transplantable murine tumours. Vet. Comp. Oncol., 2003, 1(4), 216–226.
- Yin, F., Giuliano, A. E., Law, R. E. and Van, H. A. J., Apigenin inhibits growth and induces G2/M arrest by modulating cyclinCDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer. Res., 2001, 21(1A), 413–420.
- Way, T. D., Kao, M. C. and Lin, J. K., Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activationin HER2/neu-overexpressing breast cancer cells. FEBS. Lett., 2005, 579(1), 145–152.
- Jin, X. Y. and Ren, C. S., Effect and mechanism of apigenin on VEGF expression in human breast cancer cells. Zhonghua. Zhong. Liu. Za Zhi, 2007, 29(7), 495–499.
- Lee, W. J., Chen, W. K., Wang, C. J., Lin, W. L. and Tseng, T. H., Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells. Toxicol. Appl. Pharmacol., 2008, 226(2), 178–191.
- Choi, E. J. and Kim, G. H., Apigenin induces apoptosis through a mitochondria/Caspase-pathway in human breast cancer MDAMB453 cells. J. Clin. Biochem. Nutr., 2009, 44(3), 260–265.
- Choi, E. J. and Kim, G. H., Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SKBR3 cells. J. Nutr. Biochem., 2009, 20(4), 285–290.
- Seo, H. S. et al., Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFB signaling in HER2-overexpressing breast cancer cells. Mol. Cell. Biochem., 2012, 366(1–2), 319–334.
- Mafuvadze, B., Benakanakere, I. and Hyder, S. M., Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause., 2010, 17(5), 1055–1063.
- Way, T. D., Kao, M. C. and Lin, J. K., Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/ neu-overexpressing breastcancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 2004, 279(6), 4479–4489.
- Seo, S. H., Ku, J. M., Choi, H. S., Woo, J. K., Jang, H. B., Shin, Y. C. and Ko, S. G., Induction of Caspase-dependent Apoptosis by Apigenin by inhibiting STAT3 signaling in HER2overexpressing MDA-MB-453 breast cancer cells. Anticancer Res., 2014, 34, 2869–2882.
- Bowen, L., Bin, Z., Yue, Z., Weihong, F., Yuanyuan, L. J., Weiran, Z. and Xuchen, C., Apigenin Induces p53-dependent apoptosis and G2/M arrest in breast cancer T47D cells. Chinese J. Clin. Oncol., 2012, 39(6), 315–317.
- Weiran, Z., Bin, Z., Bowen, L. and Xuchen, C., Apigenin induction of p53-independent apoptosis in MDA-MB-231 breast cancers. Chinese J. Clin. Oncol., 2013, 40(3), 134–139.
- Megan, E. H., Melanie, R. P. C., Leanne, M. D. and David, W. H., Exposure of breast cancer cells to a subcytotoxic dose of apigenin causes growth inhibition, oxidative stress, and hypophosphorylation of Akt. Exp. Mol. Pathol., 2014, 97, 211–217.
- Coral, O., Matko, K., Jing, W., Enrica, M., Krystyna, F. and Owen, A. O. C., Propolis and its active component, caffeic acid phenethyl ester (CAPE), modulate breast cancer therapeutic targets via an epigenetically mediated mechanism of action. J. Cancer. Sci. Ther., 2013, 5(10), 334–342.
- Jayaprakasam, B., Vanisree, M., Yanjun, Z., David, L. D. and Muraleedharan, G. N., Impact of alkyl esters of caffeic and ferulic acids on tumour cell proliferation, cyclooxygenase enzyme and lipid peroxidation. J. Agric. Food Chem., 2006, 54, 5375– 5381.
- Luc, H. B., Nadia, P., Jeremie, D., Benoıt, V., Marc, E. S., Gilles, A. R. and Mohamed, T., Caffeoyl and cinnamoyl clusters with anti-inflammatory and anti-cancer effects: synthesis and structure– activity relationship. New J. Chem., 2009, 33, 1932–1940.
- Qu, X. J. et al., Using caffeoyl pyrrolidine derivative LY52, a potential inhibitor of matrix metalloproteinase-2, to suppress tumour invasion and metastasis. Int. J. Mol. Med., 2006, 18(4), 609–614.
- Bailly, F., Toillon, R. A., Tomavo, O., Jouy, N., Hondermarck, H. and Cotelle, P., Antiproliferative and apoptotic effects of the oxidative dimerization product of methyl caffeate on human breast cancer cells. Bioorg. Med. Chem. Lett., 2013, 23(2), 574–578.
- Omene, C. O., Wu, J. and Frenkel, K., Caffeic acid phenethyl ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells. Invest. New. Drugs, 2012, 30(4), 1279–1288.
- Ahn, C. H., Choi, W. C. and Kong, J. Y., Chemosensitizing activity of caffeic acid in multidrug-resistant MCF-7/Dox human breast carcinoma cells. Anticancer Res., 1997, 17(3C), 1913–1917.
- Choi, J. A. et al., Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. J. Oncol., 2001, 19(4), 837–844.
- Choi, E. J., Bae, S. M. and Ahn, W. S., Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch. Pharm. Res., 2008, 31(10), 1281–1285.
- Chien, S. Y. et al., Quercetin-induced apoptosis acts through mitochondrialand caspase-3-dependent pathways in human breastcancer MDA-MB-231 cells. Hum. Exper. Toxicol., 2009, 28(8), 493–503.
- Chou, C. C. et al., Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through themitochondrial pathway in human breast cancer MCF-7 cells. Arch. Pharm. Res., 2010, 33(8), 1181–1191.
- Soyocak, A., Didem, T. C., Ayse, B., Irfan, D., Hasan, V. G., Fezan, S. M. and Ertugrul, C., The association between apoptotic Bak protein and quercetin in breast and colon cancer cell lines. FABAD J. Pharm. Sci., 2009, 34, 83–89.
- Lee, Y. K. and Park, O. J., Involvement of AMPK/mTOR/HIF-1 in anti-cancer control of quercetin in hypoxic MCF-7 cells. Food Sci. Biotechnol., 2011, 20(2), 371–375.
- Zhang, H., Zhang, M., Yu, L., Zhao, Y., He, N. and Yang, X., Antitumour activities of quercetin and quercetin-5,8-disulfonate in human colon and breast cancer cell lines. Food. Chem. Toxicol., 2012, 50(5), 1589–1599.
- Deng, X. H., Song, H. Y., Zhou, Y. F., Yuan, G. Y. and Zheng, F. G., Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro. Exp. Ther. Med., 2013, 6(5), 1155–1158.
- Du, G. et al., Dietary quercetin combining intratumoural doxorubicin injection synergistically induces rejection of establishedbreast cancer in mice. Int. Immuno. Pharmacol., 2010, 10(7), 819–826.
- Zhong, X., Wu, K., He, S., Ma, S. and Kong, L., Effects of quercetin on the proliferation and apoptosis in transplantation tumour of breast cancer in nude mice. Sichuan. Da. Xue. Bao. Yi. Xue. Ban., 2003, 34(3), 439–442.
- Chang, Y. M. and Shen, Y. L., Linalool exhibits cytotoxic effects by activating antitumour immunity. Mol., 2014, 19, 6694–6706.
- Vesna, T. S., Jasna, C. B., Gordana, C., Sonja, D. and Dragana, C. S., Dried bilberry (Vacciniummyrtillus L.) extract fractions as antioxidants and cancer cell growth inhibitors. Food Sci. Technol., 2014, 61(2), 615–621.
- Vidya, N. and Niranjali, D. S., Induction of apoptosis by Eugenol in human breast cancer. Indian J. Exp. Biol., 2011, 49, 871–878.
- Ibtehaj, A. S., Adnane, R. and Abdelilah, A., Eugenol triggers apoptosis in breast cancer cells through E2F1/survivin downregulation. BMC Cancer, 2013, 13, 600–612.
- Guoyi, M., Nurhayat, T., Husnu, C. B., Nese, K., David, S. P., Ikhlas, A. K. and Shabana, I. K., Inhibition of NF-B-mediated transcription and induction of apoptosis in human breast cancer cells by epoxypseudoisoeugenol-2-methyl butyrate. Cancer Chemother. Pharmacol., 2009, 63, 673–680.
- In, L. L., Azmi, M. N., Ibrahim, H., Awang, K. and Nagoor, N. H., 1S-1-acetoxyeugenol acetate: a novel phenylpropanoid from Alpiniaconchigera enhances the apoptotic effects of paclitaxel in MCF-7 cells through NF-B inactivation. Anticancer Drugs, 2011, 22(5), 424–434.
- Hong, T. B., Anizah, R., Thaneswary, Y., Maimunah, A. and Khoo, B. Y., Potential effects of Chrysin on MDA-MB-231 cells. Int. J. Mol. Sci., 2010, 11(3), 1057–1069.
- Yang, B. et al., Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrixmetalloproteinase10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. J. Appl. Toxicol., 2014, 34(1), 105112.
- Sun, L. P. et al., Chrysin: a histone deacetylase 8 inhibitor with anti-cancer activity and a suitable candidate for the standardization of Chinese Propolis. J. Agric. Food Chem., 2012, 60, 11748–11758.
- Lirdprapamongkol, K. et al., A flavonoid chrysin suppresses hypoxic survival and metastatic growth of mouse breast cancer cells. Oncol. Rep., 2013, 30(5), 2357–2364.
- Zhao, X. C., Tian, L., Cao, J. G. and Liu, F., Induction of apoptosis by 5,7-dihydroxy-8-nitrochrysin in breast cancer cells: the role of reactive oxygen species and Akt. Int. J. Oncol., 2010, 37(5), 1345–1352.
- Xiao, C. Z., Xiao, C. C., Fei, L., Quan, M. F., Ren, K. Q. and Cao, J. G., Regulation of the FOXO3a/Bim signaling pathway by 5,7-dihydroxy-8-nitrochrysin in MDA-MB-453 breast cancer cells. Oncol. Lett., 2013, 5(3), 929–934.
- Huynh, H., Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol. J. Cell. Physio., 2004, 198, 197–208.
- Oh, S. M., Kim, Y. P. and Chung, K. H., Biphasic effects of kaempferol on the estrogenicity in human breast cancer cells. Arch. Pharm. Res., 2006, 29(5), 354–362.
- Ajeng, D. et al., A. kaempferol-3-O-rhamnoside isolated from the leaves of Schimawallichii Korth. Inhibits MCF-7 breast cancer cell proliferation through activation of the caspase cascade pathway. Oncol. Lett., 2012, 3(5), 1069–1072.
- Wang, Q., Min, H., Yu, H., Zhang, J. S., Zhou, S. F., Zeng, R. Q. and Yang, X. B., Synthesis, characterization, DNA interaction, and antitumour activities of mixed-ligand metal complexes of kaempferol and 1,10-phenanthroline/2,20-bipyridine. Med. Chem. Res., 2014, 23, 2659–2666.
- Kang, G. Y. et al., Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells. Eur. J. Pharmacol., 2009, 6(11), 17–21.
- Hao, Q., Zhao, P., Niu, J., Wang, J., Yu, J. and Xue, X., Effect of ferulic acid on proliferation and mechanism in human breast cancer cells. ZhongguoZhong. Yao. ZaZhi., 2010, 35(20), 2752–2755.
- Areti, S., Zoi, P., Evi, L. and Paraskevi, M., Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) + + transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin. Biochem., 2009, 42, 1358–1362.
- Zhang, T., Chen, H. S., Wang, L. F., Bai, M. H., Wang, Y. C., Jiang, X. F. and Liu, M., Ellagic acid exerts anti-proliferation effects via modulation of Tgf-/Smad3 signaling in MCF-7 breast cancer cells. Asian. Pac. J. Cancer. Prev., 2014, 15(1), 273–276.
- Neng, W. et al., Ellagic acid, a phenolic compound, exerts antiangiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast. Cancer. Res. Treat., 2012, 134(3), 943–955.
- Kim, H. A., Lee, R. A., Moon, B. I. and Choe, K. J., Ellagic acid shows different anti-proliferative effects between the MDA-MB-231 and MCF-7 human breast cancer cell lines. J. Breast Cancer, 2009, 12(2), 85–91.
- Jack, N. L., Rishipal, R. B., Alfred, T., Hiba, A. B. and Robert, T., In vitro anti-proliferative activities of ellagic acid. J. Nutr. Biochem., 2004, 15, 672–678.
- Samer, H. H. A., Mothanna, A. Q., Mohamed, E. Z., Maznah, I. and Mohd, Z. H., Cytotoxicity and antimicrobial activity studies of an ellagic acid-zinc layered hydroxide intercalation compound. Sci. Adv. Mater., 2013, 5(10), 1–10.
- Choi, E. J., Hesperetin induced G1-phase cell cycle arrest in human breast cancer MCF-7 cells: involvement of CDK4 and p21. Nutr. Cancer, 2007, 59(1), 115–119.
- Yong, Y., Joy, W., Boom, K., Xiaohong, F., Haifa, S. and Mauro, F., Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell. Biochem. Funct., 2013, 31(5), 1–10.
- Lan, Y., Franky, L. C., Shiuan, C. and Lai, K. L., The citrus flavononehesperetin inhibits growth of aromatase-expressing MCF-7 tumour in ovariectomized athymic mice. J. Nutr. Biochem., 2012, 23, 1230–1237.
- Fengjuan, L., Simon, C., Cheung, W. H., Franky, L. C., Shiuan, C. and Lai, K. L., The citrus flavononehesperetin prevents letrozoleinduced bone loss in a mouse model of breast cancer. J. Nutr. Biochem., 2013, 24, 1112–1116.
- Hongzhuan, X. et al., Antitumour activity of Chinese propolis in human breast cancer MCF-7 and MDA-MB-231 cells. Evid. Based. Complement. Alternat. Med., 2014, 80120, 11; http://dx.doi.org/10.1155/2014/280120.
- Tessa, J. M., Xinhai, Y. and David, H. S., Growth of a human mammary tumour cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E and A. Breast Cancer Res., 2006, 8(2), 1–11.
- So, F. N., Guthrie, N., Chambers, N. F. and Carroll, K. K., Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett., 1997, 112, 127–133.
- A CFD Investigation of Mixing Profiles within a Micro-Coiled Flow Inverter
Abstract Views :202 |
PDF Views:0
Authors
Affiliations
1 Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, Johor Bahru, Johor – 81300, MY
1 Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, Johor Bahru, Johor – 81300, MY
Source
Indian Journal of Science and Technology, Vol 10, No 7 (2017), Pagination:Abstract
Background/Objectives: Due to the low Reynolds number (Re) in microfluidic domain, the predominant laminar flow might inhibit effective mixing in micro-Coiled Flow Inverter (mCFI). Fluid dynamics within the mCFI was simulated with Computational Fluid Dynamics (CFD) software to investigate the mixing profile. Methods/Statistical Analysis: Fluid flow was simulated with the software FLUENT with Species Transport (ST) setting, to replicate the mixing of two water bodies. Geometry of the mCFI was designed with a tubing diameter of 0.5 mm and curvature ratio of λ = 10. Fluid flow rate was adjusted to attain 25≤ Re ≤ 250. Findings: A mixing time of 0.59s was achieved with Re = 250. However complete mixing was still achievable even in Re = 25 albeit with a longer mixing time. Application/Improvements: Flow inversion is improved the mixing condition in micro-structured tubing, in enhancement of the diffusive mixing in microfluidics.Keywords
Flow Inversion and Computational Fluid Dynamics (CFD), Micro-Coiled Flow Inverter (Mcfi), Reynolds Number.Full Text
- Folic Acid Decorated Chitosan Nanoparticles and its Derivatives for the Delivery of Drugs and Genes to Cancer Cells
Abstract Views :340 |
PDF Views:80
Authors
Agnes Aruna John
1,
Saravana Kumar Jaganathan
2,
Manikandan Ayyar
3,
Navaneetha Pandiyaraj Krishnasamy
4,
Rathanasamy Rajasekar
5,
Eko Supriyanto
6
Affiliations
1 Universiti Teknologi Malaysia, Skudai 81310, Johor, MY
2 2Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, VN
3 Department of Chemistry, Bharath Institute of Higher Education and Research, Bharath University, Chennai 600 073, IN
4 Department of Physics, Sri Shakthi Institute of Engineering and Technology, Coimbatore 641 062, IN
5 Department of Mechanical Engineering, Kongu Engineering College, Erode-638 052, IN
6 IJN-UTM Cardiovascular Engineering Centre, Department of Clinical Sciences, Universiti Teknologi Malaysia, Skudai 81300, Johor, MY
1 Universiti Teknologi Malaysia, Skudai 81310, Johor, MY
2 2Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, VN
3 Department of Chemistry, Bharath Institute of Higher Education and Research, Bharath University, Chennai 600 073, IN
4 Department of Physics, Sri Shakthi Institute of Engineering and Technology, Coimbatore 641 062, IN
5 Department of Mechanical Engineering, Kongu Engineering College, Erode-638 052, IN
6 IJN-UTM Cardiovascular Engineering Centre, Department of Clinical Sciences, Universiti Teknologi Malaysia, Skudai 81300, Johor, MY
Source
Current Science, Vol 113, No 08 (2017), Pagination: 1530-1542Abstract
Nanotechnology offers a number of nanoscale implements for medicine. Among these, nanoparticles are revolutionizing the field of drug and gene delivery. Chitosan is a natural polymer which provides a profitable tool to an innovative delivery system due to its inherent physicochemical and biological characteristics. Chitosan nanoparticles are promising drug and gene delivery carriers because of small size, better stability, low toxicity, inexpensiveness, simplicity, easy fabrication and versatile means of administration. Chitosan can also be easily modified chemically due to the presence of reactive functional hydroxide and amine groups. Folic acid is commonly engaged as a ligand, for targeting cancer cells, as its receptor, that transports folic acid into the cells through endocytosis and is over-expressed on the surface of several human epithelial cancer cells. Integrating folic acid into chitosan-based drug delivery inventions directs the systems with a well-organized targeting ability. The present review outlines several illustrations of this versatile system based on folate decorated chitosan, which have shown potential as auspicious delivery systems published over the past few years. In addition, it is probable to formulate chitosan nanocarriers that exhibit manifold usage beyond targeted delivery, such as nanotheranostics and cancer stem cell therapy.Keywords
Cancer, Chitosan, Doxorubicin, Drug Delivery, Folic Acid, 5-fluorouracil, Gene Delivery.Full Text
References
- https://www.cancer.org/content/dam/cancer-org/research/cancer-factsandstatistics/annual-cancer-facts-and-figures/2017/cancer-facts-andfigures2017.pdf (accessed on 31 May 2017).
- https://www.cancer.org/treatment/treatments-and-side-effects/treatmenttypes/chemotherapy/how-chemotherapy-drugs-work.html (accessed on 31 May 2017).
- http://www.understandingnano.com/cancer-treatment-nanotechnology.html (accessed on 31 May 2017).
- Dand, N. M., Patel, P. B., Ayre, A. P. and Kadam, V. J., Polymeric micelles as a drug carrier for tumour targetting. Chron. Young Sci., 2013, 4, 94–101.
- Saeed, S. E., Mahnaz, T., Mehdi, F., Javad, M. and Bahram, R., Effects of Levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells. Neurosciences, 2013, 18(3), 281–283.
- Torchilin, V., Tumour delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev., 2011, 63, 131–135.
- Maeda, H., Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control Release, 2012, 164, 138–144.
- Tsume, Y., Hilfinger, J. M. and Amidon, G. L., Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity andmetabolic stability. Mol. Pharm., 2008, 5(5), 717–727.
- Song, H. et al., Folic acid–chitosan conjugated nanoparticles for improving tumour-targetted drug delivery. BioMed. Res. Int., 2013, 1–6.
- Lu, Y. and Low, P. S., Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54(5), 675–693.
- Prabaharan, M., Chitosan-based nanoparticles for tumour-targetted drug delivery. Int. J. Biol. Macromolec., 2015, 72, 1313–1322.
- Agarwal, M., Nagar, D. P., Srivastava, N. and Agarwal, M. K., Chitosan nanoparticles-based drug delivery: an update. Int. J. Adv. Multidiscip. Res., 2015, 2(4), 1–13.
- Patel, M. P., Patel, R. R. and Patel, J. K., Chitosan mediated targetted drug delivery system: a review. J. Pharm. Pharma. Sci., 2010, 13, 536–557.
- Jie, J., Wu, W. Z., Zhong, Z. R., Guang, X. T. X., Shu, L. Z. and Wang, L., Recent advances of chitosan nanoparticles. Int. J. Nanomedicine, 2011, 6, 765–774.
- Wu, J. et al., Chitosan nano carriers loading anti-tumour drugs. J. Nano. Res., 2015, 32, 113–127.
- Shia, J. et al., Immunohistochemical expression of folate receptoralpha in ovarian epithelial neoplasms bears clinical and pathological significance. Mod. Pathol., 2009, 22, 237a.
- LeBlanc, J. G., de Giori, G. S., Smid, E. J., Hugenholtz, J. and Sesma, F., Folate production by lactic acid bacteria and other food-grade microorganisms. Current Research and Educational Topics and Trends in Applied Microbiology (ed. Méndez-Vilas, A.), 2007, pp. 329–339.
- Amidi, M., Mastrobattista, E., Jiskoot, W. and Hennink, W. E., Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev., 2010, 62(1), 59–82.
- Prabaharan, M. and Mano, J. F., Chitosan-based particles as controlled drug delivery systems. Drug Deliv., 2005, 12, 41–57.
- Tiyaboonchai, W. and Limpeanchob, N., Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int. J. Pharm., 2007, 329, 142–149.
- Lankalapalli, S. and Kolapalli, V. R. M., Polyelectrolyte complexes: a review of their applicability in drug delivery technology. Indian J. Pharm. Sci., 2009, 71(5), 481–487.
- Kumar, N., Patel, A. K., Kumari, N. and Kumar, A., A review on chitosan nanoparticles for cancer treatment. Int. J. Nanomater. Bios., 2014, 4(4), 63–65.
- Huang, H. Y., Shieh, Y. T., Shih, C. M. and Twu, Y. K., Magnetic chitosan/iron (II, III) oxide nanoparticles prepared by spraydrying. Carbohydr Polym., 2010, 81(4), 906–910.
- Goldberg, M., Langer, R. and Jia, X., Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater. Sci. Polym. Ed., 2007, 18(3), 241–268.
- Guaragna, A., Chiaviello, A., Paolella, C., D’Alonzo, D. and Palumbo, G., Synthesis and evaluation of folate-based chlorambucil delivery systems for tumour-targetted chemotherapy. Bioconjug. Chem., 2011, 23(1), 84–96.
- Vllasaliu, D., Casettari, L., Bonacucina, G., Cespi, M., Palmieri, G. P. and Illum, L., Folic acid conjugated chitosan nanoparticles for tumour targetting of therapeutic and imaging agents, Pharm. Nanotechnol., 2013, 1, 184–203.
- Chakraborty, S. P., Sahu, S. K., Pramanik, P. and Roy, S., Biocompatibility of folate–modified chitosan nanoparticles. Asian Pac. J. Trop. Biomed., 2012, 2(3), 215–219.
- Sahu, S. K., Maiti, S., Maiti, T. K., Ghosh, S. K. and Pramanik, P., Folate-decorated succinylchitosan nanoparticles conjugated with doxorubicin for targetted drug delivery. Macromol. Biosci., 2011, 11(2), 285–295.
- Jiang, H. L. et al., The suppression of lung tumourigenesis by aerosol-delivered folatechitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signalling pathway. Biomater., 2009, 30(29), 5844–5852.
- Bhattacharya, S., Li, X., Nyshadham, J. and Jasti, B., Folate receptor targetted delivery systems: a novel micellar drug delivery approach. Curr. Trends Biotechnol. Pharm., 2010, 4(1), 490–509.
- Ke, J. H., Lin, J. J., Carey, J. R., Chen, J. S., Chen, C. Y. and Wang, L. F., A specific tumour-targetting magnetofluorescent nanoprobe for dual-modality molecular imaging. Biomaterials, 2010, 31, 1707–1715.
- Bahrami, B. et al., Folate-conjugated nanoparticles as a potent therapeutic approach in targetted cancer therapy. Tumour Biol., 2015, 36(8), 5727–5742.
- Park, J. H., Lee, S., Park, K., Kim, K. and Kwan, I. C., Smart chitosanbased stimuli-responsive nanocarriers for the controlled delivery of hydrophobic pharmaceuticals. Macromolecules. 2011, 44, 1298–1302.
- Neha, M. D., Pranav, B. P., Anita, A. and Vilasrau, J. K., Polymeric micelles as a drug carrier for tumour targetting. Chron. Young Sci., 2013, 4(2), 94–101.
- Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S. and Gabizon, A., Nuclear delivery of doxorubicin via folatetargetted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6(5), 1949–1957.
- Yang, H. C. and Hon, M. H., The effect of the molecular weight of chitosan nanoparticles and its application on drug delivery. Microchem. J., 2009, 92(1), 87–91.
- Parveen, S. and Sahoo, S. K., Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targetted delivery to retinoblastoma. Cancer Nanotechnol., 2010, 1(1–6), 47–62.
- Fan, L. et al., Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targetted drug delivery and overcome multidrug resistance. Biomaterials, 2010, 31(21), 5634–5642.
- Shen, J. M., Tang, W. J., Zhang, X. L., Chen, T. and Zhang, H. X., A novel carboxymethyl chitosan-based folate/Fe3O4/CdTe nanoparticle for targetted drug delivery and cell imaging. Carbohydr. Polym., 2012, 88(1), 239–249.
- Hu, H., Tang, C. and Yin, C., Folate conjugated trimethylchitosan/ graphene oxide nanocomplexes as potential carriers for drug and gene delivery. Mater Lett., 2014, 125, 82–85.
- Yu, J. et al., Folic acid conjugated glycol chitosan micelles for targetted delivery of doxorubicin: preparation and preliminary evaluation in vitro. J. Biomater. Sci. Polym. Ed., 2013, 24(5), 606–620.
- Chen, D. et al., pH responsive mechanism of a deoxycholic acid and folate comodified chitosan micelle under cancerous environment. J. Phys. Chem. B, 2013, 117(5), 1261–1268.
- Manaspon, C., Viravaidya-Pasuwat, K. and Pimpha, N., Preparation of folate-conjugated pluronic f127/chitosan core-shell nanoparticles encapsulating doxorubicin for breast cancer treatment. J. Nanomater., 2012, 2012, 1–11.
- Depan, D., Shah, J. and Misra, R. D. K., Controlled release of drug from folate-decorated and graphene mediated drug delivery system: Synthesis, loading efficiency, and drug release response. Mater. Sci. Eng. C, 2011, 31(7), 1305–1312.
- Huang, H., Yuan, Q., Shah, J. S. and Misra, R. D. K., A new family of folate decorated carbon nanotube-mediated drug delivery system: synthesis and drug delivery response. Adv. Drug Deliv. Rev., 2011, 63(14–15), 1332–1339.
- Lee, K. D., Choi, S. H., Kim, D. H., Lee, H. Y. and Choi, K. C., Self-organized nanoparticles based on chitosan-folic acid and dextran succinate-doxorubicin conjugates for drug targetting. Arch. Pharm. Res., 2014, 37, 1546–1553.
- Ji, Z. et al., Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J. Colloid Interf. Sci., 2012, 365(1), 143–149.
- Wang, Y., Li, P., Chen, L., Gao, W., Zeng, F. and Kong, L. X., Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles. Drug Deliv., 2015, 22(2), 191–198.
- Mathew, M. E., Mohan, J. C., Manzoor, K., Nair, S. V., Tamura, H. and Jayakumar, R., Folate conjugated carboxymethyl chitosan manganese doped zinc sulphide nanoparticles for targetted drug delivery and imaging of cancer cells. Carbohydr. Polym., 2010, 80(2), 443–449.
- Kadagi, M. et al., Synthesis, characterisation of 5-Fu loaded chitosan nanoparticles, Glob. J. Res. Anal., 2014, 3(9), 114–116.
- Yu, S. et al., Inorganic nanovehicle for potential targetted drug delivery to tumour cells, tumour optical imaging, ACS Appl. Mater. Interf., 2015, 7, 5089–5096.
- Li, H. L., He, Y. X., Gao, Q. H. and Wu, G. H., Folatepolyethylene glycol conjugated carboxymethyl chitosan for tumour-targetted delivery of 5-fluorouracil. Mol. Med. Rep., 2014, 9, 786–792.
- Yang, Z. M., Peng, Z. and Zhou, M., Drug-loading chitosan polymer microsphere with targetted and slow-release function and its characteristics. J. Funct. Mat., 2013, 44(12), 1703–1708.
- Blanco, M. D., Guerrero, S. and Benito, M., In vitro and in vivo evaluation of a folate-targetted copolymeric submicrohydrogel based on n-isopropylacrylamide as 5-fluorouracil delivery system. Polym., 2011, 3, 1107–1125.
- Vasanti, S. and Preeti, S., Paclitaxel nanoparticles – an approach to improve the bioavailability. Int. J. Pharm. Sci. Rev. Res., 2014, 27(1), 200–208.
- You, J., Li, X., De Cui, F., Du, Y. Z., Yuan, H. and Hu, F. Q., Folate-conjugated polymer micelles for active targetting to cancer cells: preparation, in vitro evaluation of targetting ability and cytotoxicity. Nanotechnol., 2008, 19(4), 1–9.
- Lan, G. J., Sen-ming, W., Xi-gang, H., Man-ming, C. A. O. and Ji-ren, Z., Synthesis and characterization of folic acid-conjugated chitosan nanoparticles as a tumour-targetted drug carrier. J. South Med. Univ., 2008, 28(12), 2183–2186.
- Qu, D., Lin, H., Zhang, N., Xue, J. and Zhang, C., In vitro evaluation on novel modified chitosan for targetted antitumour drug delivery. Carbohydr. Polym., 2013, 92(1), 545–554.
- Wang, F. et al., Tissue distribution and pharmacokinetics evaluation of DOMC-FA micelles for intravenous delivery of PTX. J. Drug Deliv., 2013, 21(2), 137–145.
- Huang, S., Wan, Y., Wang, Z. and Wu, J., Folate-conjugated chitosan– polylactide nanoparticles for enhanced intracellular uptake of anticancer drug. J. Nanopart. Res., 2013, 15, 1–15.
- Sahu, S. K., Maiti, S., Maiti, T. K., Ghosh, S. K. and Pramanik, P., Hydrophobically modified carboxymethyl chitosan nanoparticles targetted delivery of paclitaxel. J. Drug Target, 2011, 19(2), 104–113.
- Hou, Z. et al., Both FA- and mPEG-conjugated chitosan nanoparticles for targetted cellular uptake and enhanced tumour tissue distribution. Nanoscale Res. Lett., 2011, 6(1), 563–574.
- Jia, M., Li, Y. and Yang, X., Development of both methotrexate and mitomycin c loaded pegylated chitosan nanoparticles for targetted drug codelivery and synergistic anticancer effect. Appl. Mater. Interfaces, 2014, 6, 11413–11423.
- Patel, M. P., Patel, R. R. and Patel, J. K., Chitosan mediated targetted drug delivery system: a review. J. Pharm. Pharmaceut. Sci., 2010, 13(3), 536–557.
- Lin, J., Li, Y. and Wu, H., Tumour-targetted co-delivery of mitomycin C and 10-hydroxycamptothecin via micellar nanocarriers for enhanced anticancer efficacy. RSC Adv., 2015, 5, 23022–23033.
- Li, Y., Wu, H. and Jia, M., Therapeutic effect of folate-targetted and pegylated phytosomes loaded with a Mitomycin C-soybean phosphatidyhlcholine complex. Mol. Pharmaceu., 2014, 11, 3017–3026.
- Morris, V. B., Pillai, C. K. S. and Sharma, C. P., Folic acid conjugated depolymerized quaternized chitosan as potential targetted gene delivery vector. Polym. Int., 2011, 60(7), 1097–106.
- Zhou, Y., Chen, J. and Wang, H., Synthesis and characterization of folate-poly(ethylene glycol) chitosan graft-polyethylenimine as a non-viral carrier for tumour-targetted gene delivery. Afr. J. Biotechnol., 2011, 10(32), 6120–6129.
- Kim, Y. K., Tehrani, A. M., Lee, J. H., Cho, C. S., Cho, M. H. and Jiang, H. L., Therapeutic efficiency of folated poly(ethylene glycol)chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer. Int. J. Nanomed., 2013, 8, 1489–1498.
- Gaspar, V. M., Costa, E. C., Queiroz, J. A., Pichon, C., Sousa, F. and Correia, I. J., Folate-targetted multifunctional amino acidchitosan nanoparticles for improved cancer therapy. Pharm. Res., 2015, 32, 562–577.
- Guana, Q. and Wang, M., Fabrication and characteristics of genedelivering nanodevices based on Au-Ag@CS-FA hybrid particles. Mater. Sci. Forum, 2015, 815, 401–406.
- Lai, W. F. and Lin, M. C., Folate-conjugated chitosanpoly( ethylenimine) copolymer as an efficient and safe vector for gene delivery in cancer cells. Curr. Gene Ther., 2015, 15(5), 472– 480.
- Yan, C. Y., Gu, J. W. and Hou, D. P., Synthesis of tat tagged and folate modified N-succinyl-chitosan self-assembly nanoparticles as a novel gene vector. Int. J. Biol. Macromol., 2015, 72, 751–756.
- Shi, B., Zhang, H., Bi, J. and Dai, S., Endosomal pH responsive polymers for efficient cancer targetted gene therapy. Colloids Surf. B, 2014, 119, 55–65.
- Li, T. S., Yawata, T. and Honke, K., Efficient siRNA delivery and tumour accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targetted ovarian cancer gene therapy. Eur. J. Pharm. Sci., 2014, 52, 48–61.
- Yu, B., Tang, C. and Yin, C., Enhanced antitumour efficacy of folate modified amphiphilic nanoparticles through co-delivery of chemotherapeutic drugs and genes. Biomaterials, 2014, 35(24), 6369–6378.
- Wang, M., Hu, H. and Sun, Y., A pH-sensitive gene delivery system based on folic acid-PEG-chitosan-PAMAM-plasmid DNA complexes for cancer cell targetting. Biomaterials, 2013, 34(38), 10120–10132.
- Zheng, Y., Song, X. and He, G., Receptor-mediated gene delivery by folate-poly(ethylene glycol)-grafted-trimethyl chitosan in vitro. J. Drug Target, 2011, 19(8), 647–656.
- Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S. and Leamon, C. P., Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem., 2005, 338, 284–293.
- Bwatanglang, I. B., Mohammad, F. and Yusof, N. A., Folic acid targetted Mn : ZnS quantum dots for theranostic applications of cancer cell imaging and therapy. Int. J. Nanomed., 2016, 11, 413–428.